Title: humanized antibody
Long Title: IUPAC Gold Book - humanized antibody
DOI: 10.1351/goldbook.13229
Status: current

Definition
Genetically engineered monoclonal antibody of non-human origin in which all but the antigen-binding complementarity-determining region (CDR) sequences have been replaced with sequences derived from human antibodies.

Note
This procedure is carried out to minimize the immunogenicity of therapeutic, monoclonal antibodies.

Related Terms
- complementarity-determining region (CDR): https://goldbook.iupac.org//terms/view/13029
- therapeutic: https://goldbook.iupac.org//terms/view/12878

Source
- PAC, 2012, 84, 1113. 'IUPAC glossary of terms used in immunotoxicology (IUPAC Recommendations 2012)' on page 1178 (https://doi.org/10.1351/PAC-REC-11-06-03)

Other Outputs
- html: https://goldbook.iupac.org/terms/view/13229/html
- json: https://goldbook.iupac.org/terms/view/13229/json
- xml: https://goldbook.iupac.org/terms/view/13229/xml

Citation: Citation: 'humanized antibody' in IUPAC Compendium of Chemical Terminology, 5th ed. International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13229
License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/) for individual terms.
Collection: If you are interested in licensing the Gold Book for commercial use, please contact the IUPAC Executive Director at executivedirector@iupac.org .
Disclaimer: The International Union of Pure and Applied Chemistry (IUPAC) is continuously reviewing and, where needed, updating terms in the Compendium of Chemical Terminology (the IUPAC Gold Book). Users of these terms are encouraged to include the version of a term with its use and to check regularly for updates to term definitions that you are using.
Accessed: 2026-04-18T00:21:01+00:00